This study demonstrates that 68Ga-PSMA PET/CT imaging may serve as a valuable tool in the staging and risk stratification of prostate cancer, particularly when assessing tumor aggressiveness in relation to histopathological grading. This evidence concerns the gene FOLH1 and prostate carcinoma.